Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 9;5:183. doi: 10.1038/s41392-020-00230-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — VDR impairs the CSC phenotype and drug resistance in CRC. a Immunoblotting of VDR in CC tissue adherent (Ad) cells and CSCs, RKO (Ad) cells and RKO-SLCs, and SW480 (Ad) cells and SW480-SLCs. CSCs, cancer stem cells; SLCs, stem-like cells. b Immunoblotting of VDR in HCT116 and oxaliplatin-resistant HCT116 (HCT116-OXA) cells. c Immunoblotting of VDR in CC tissue CSCs and RKO-SLCs infected with negative control and VDR overexpression lentiviruses. d Representative images (left) and quantified data (right) for tumor spheres (with diameters larger than 50 µm) formed by control and VDR-overexpressing CC tissue CSCs. Scale bars: upper, 200 μm; lower, 50 μm. Student’s t-test. e Limiting dilution assay of control and VDR-overexpressing CC tissue CSCs. Wells not containing tumor spheres (with diameters larger than 50 μm) for each cell plating density were used for the calculations after 1–2 weeks. f The percentages of CD133-positive cells among control and VDR-overexpressing CC tissue CSCs and RKO-SLCs were evaluated using flow cytometric analysis. Student’s t-test. g IC50 of oxaliplatin in control and VDR-overexpressing CC tissue CSCs treated with oxaliplatin at pH 7.4 and 6.8. Student’s t-test. h–j Immunoblotting of VDR in CC tissue-adherent cells and RKO cells treated with control or VDR-targeting shRNA (h). Representative images (i) and quantified data (j) for tumor spheres (with diameters larger than 50 µm) formed by CC tissue adherent and RKO cells treated with control or VDR-targeting shRNA. Scale bars: 200 μm. Student’s t-test. k Limiting dilution assay of CC tissue-adherent cells treated with control or VDR-targeting shRNA. l Immunoblotting of the stemness markers CD133 and SOX2 in CC tissue-adherent cells treated with control or VDR-targeting shRNA. m The percentages of CD133-positive cells among CC tissue adherent and RKO cells treated with control or VDR-targeting shRNA were evaluated using flow cytometric analysis. Student’s t-test. n IC50 of oxaliplatin in CC tissue-adherent cells treated with control or VDR-targeting shRNA and with oxaliplatin. Student’s t-test. Three independent experiments were performed to obtain the data in d–g, j, k, m, and n. The data are shown as the mean ± SD; *P < 0.05, **P < 0.01, and ***P < 0.001